Krystal Biotech (NASDAQ:KRYS) Insider Sells $6,580,250.00 in Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $263.21, for a total value of $6,580,250.00. Following the completion of the transaction, the insider directly owned 1,403,155 shares of the company’s stock, valued at approximately $369,324,427.55. The trade was a 1.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Krystal Biotech Stock Down 2.6%

KRYS traded down $6.64 during trading on Friday, hitting $253.69. The company’s stock had a trading volume of 244,393 shares, compared to its average volume of 308,893. The stock has a market capitalization of $7.42 billion, a price-to-earnings ratio of 37.04 and a beta of 0.49. Krystal Biotech, Inc. has a 12 month low of $122.80 and a 12 month high of $298.30. The firm’s 50 day moving average price is $269.86 and its two-hundred day moving average price is $218.28.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Tuesday, February 17th. The company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.08. The business had revenue of $107.11 million for the quarter, compared to analysts’ expectations of $105.30 million. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%. On average, sell-side analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Analyst Upgrades and Downgrades

KRYS has been the subject of several recent research reports. Guggenheim increased their target price on shares of Krystal Biotech from $224.00 to $284.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Chardan Capital boosted their price objective on Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Zacks Research cut shares of Krystal Biotech from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. The Goldman Sachs Group lifted their price objective on shares of Krystal Biotech from $206.00 to $327.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Finally, Citigroup increased their target price on shares of Krystal Biotech from $336.00 to $371.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $326.25.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Royal Bank of Canada grew its position in Krystal Biotech by 145.2% during the first quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock valued at $294,000 after acquiring an additional 964 shares during the last quarter. AQR Capital Management LLC increased its position in Krystal Biotech by 29.9% during the 1st quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock valued at $2,187,000 after purchasing an additional 2,792 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Krystal Biotech by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock worth $2,870,000 after buying an additional 688 shares in the last quarter. Empowered Funds LLC purchased a new position in shares of Krystal Biotech in the 1st quarter valued at approximately $218,000. Finally, Envestnet Asset Management Inc. lifted its position in Krystal Biotech by 21.9% during the second quarter. Envestnet Asset Management Inc. now owns 15,116 shares of the company’s stock valued at $2,078,000 after buying an additional 2,717 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.